Posted by Michael Wonder on 09 Dec 2021
Henlius' fourth biologic bevacizumab biosimilar approved by National Medical Products Administration
3 December 2021 - Shanghai Henlius Biotech announced that bevacizumab biosimilar, developed and manufactured by Henlius independently, has been approved by the National Medical Products Administration .
It is indicated for the treatment of metastatic colorectal cancer and unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer.
